A number of small molecules targeting the β-catenin BCL9 interface have shown promise in APC-deficient cells both in vitro and in vivo23,34, revealing that targeting of BCL9 and BCL9l may offer a therapeutic window in CRC. This evidence concerns the gene APC and colorectal carcinoma.